COGT logo

COGENT BIOSCIENCES INC

COGTNASDAQ
๐Ÿ† #1227 by market capUS Equity
$26.73โ€”
Last available close ยท quote unavailable
๐Ÿ””
Track COGT
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ–ผ 6.3%
14dโ–ผ 15.5%
30dโ–ผ 14.3%
ytdโ–ผ 24.7%
1yโ–ผ 27.2%
๐ŸฆMarket Cap
$4.83B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
โ€”
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
208.4x
Expensive
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
โ€”
52-Week Range
$26.36 โ€“ $43.73
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
173.5M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
208.4x
EPS (TTM)
$-2.49
Dividend Yield
โ€”
COGT logo

COGENT BIOSCIENCES INC

COGT
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About COGENT BIOSCIENCES INC

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.